Lymphocyte phospho-ser-9-GSK-3β/total GSK-3β protein levels ratio is not affected by chronic lithium or valproate treatment in euthymic patients with bipolar disorder

Abed N. Azab, Ella Vainer, Galila Agam, Yuly Bersudsky

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Background Glycogen synthase kinase-3 (GSK-3) inhibition by lithium has been well established in vitro, but proof that this biochemical effect mediates lithium's beneficial action in patients with bipolar disorder is lacking. We studied whether lymphocyte GSK-3β activity measured indirectly in lithium- or valproate (VPA)-treated euthymic patients with bipolar disorder is different from controls. Methods Lymphocyte total and Ser-9-phospho-GSK-3β (inactive) levels were measured by Western blotting. Forty-seven patients with bipolar disorder and 32 age- and sex-matched control subjects were studied. Results No significant differences were found between lithium- and VPA-treated patients and controls in phospho-GSK-3β, total GSK-3β, or their ratio. Conclusions The data do not support the concept that in vivo, during chronic treatment of bipolar illness, GSK-3β is inhibited either by lithium or by VPA.

Original languageEnglish
Pages (from-to)226-230
Number of pages5
JournalJournal of Clinical Psychopharmacology
Volume37
Issue number2
DOIs
StatePublished - 1 Apr 2017

Keywords

  • VPA
  • bipolar disorder
  • glycogen synthase kinase-3
  • lithium
  • therapeutic mechanism

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Lymphocyte phospho-ser-9-GSK-3β/total GSK-3β protein levels ratio is not affected by chronic lithium or valproate treatment in euthymic patients with bipolar disorder'. Together they form a unique fingerprint.

Cite this